JP2023545521A - 抗ｐｄ－１／ｃｄ４０二重特異性抗体及びその使用 - Google Patents

抗ｐｄ－１／ｃｄ４０二重特異性抗体及びその使用 Download PDF

Info

Publication number
JP2023545521A
JP2023545521A JP2023523084A JP2023523084A JP2023545521A JP 2023545521 A JP2023545521 A JP 2023545521A JP 2023523084 A JP2023523084 A JP 2023523084A JP 2023523084 A JP2023523084 A JP 2023523084A JP 2023545521 A JP2023545521 A JP 2023545521A
Authority
JP
Japan
Prior art keywords
amino acid
seq
cdr1
chain variable
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023523084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545521A5 (https=
Inventor
バイホン リュウ
ユイ ヤン
ユエレイ シェン
Original Assignee
ユーキュア（ベイジン）バイオファーマ カンパニーリミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーキュア（ベイジン）バイオファーマ カンパニーリミテッド filed Critical ユーキュア（ベイジン）バイオファーマ カンパニーリミテッド
Publication of JP2023545521A publication Critical patent/JP2023545521A/ja
Publication of JP2023545521A5 publication Critical patent/JP2023545521A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023523084A 2020-10-14 2021-10-13 抗ｐｄ－１／ｃｄ４０二重特異性抗体及びその使用 Pending JP2023545521A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/120918 2020-10-14
CN2020120918 2020-10-14
CN2021085335 2021-04-02
CNPCT/CN2021/085335 2021-04-02
PCT/CN2021/123438 WO2022078357A1 (en) 2020-10-14 2021-10-13 Anti-pd-1/cd40 bispecific antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023545521A true JP2023545521A (ja) 2023-10-30
JP2023545521A5 JP2023545521A5 (https=) 2024-10-24

Family

ID=81207517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523084A Pending JP2023545521A (ja) 2020-10-14 2021-10-13 抗ｐｄ－１／ｃｄ４０二重特異性抗体及びその使用

Country Status (11)

Country Link
US (1) US20230220082A1 (https=)
EP (1) EP4229096A4 (https=)
JP (1) JP2023545521A (https=)
KR (1) KR20230092932A (https=)
CN (1) CN116390755A (https=)
AU (1) AU2021359495A1 (https=)
BR (1) BR112023006989A2 (https=)
CA (1) CA3197463A1 (https=)
IL (1) IL302042A (https=)
MX (1) MX2023004275A (https=)
WO (1) WO2022078357A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117624372A (zh) * 2022-08-26 2024-03-01 北京天广实生物技术股份有限公司 靶向cd40和pd-l1的抗体及其用途
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
KR20250071228A (ko) * 2022-09-20 2025-05-21 커러스 바이오로직스 피티와이 엘티디 고갈된 면역 세포를 구제하는 방법
CN120584137A (zh) * 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019161536A1 (en) * 2018-02-23 2019-08-29 Eucure (Beijing) Biopharma Co. , Ltd Anti-pd-1 antibodies and uses thereof
JP2019534292A (ja) * 2016-11-02 2019-11-28 アペクシジェン， インコーポレイテッド 組み合わせた抗ｃｄ４０抗体および使用方法
WO2020014974A1 (en) * 2018-07-20 2020-01-23 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7575100B2 (ja) * 2018-11-13 2024-10-29 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫細胞活性化のための二重特異性抗体
KR20220103957A (ko) * 2019-10-23 2022-07-25 리브젠 바이오파마 홀딩스 리미티드 항-cd40 결합 분자 및 이를 포함하는 이중-특이적 항체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019534292A (ja) * 2016-11-02 2019-11-28 アペクシジェン， インコーポレイテッド 組み合わせた抗ｃｄ４０抗体および使用方法
WO2019161536A1 (en) * 2018-02-23 2019-08-29 Eucure (Beijing) Biopharma Co. , Ltd Anti-pd-1 antibodies and uses thereof
WO2020014974A1 (en) * 2018-07-20 2020-01-23 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Novel bispecific molecules combining HERA-CD40L with anti-CEA or with anti-PD-L1 for targeting", POSTER NUMBER: 4460, AACR ANNUAL MEETING 2020, JPN6026012157, June 2020 (2020-06-01), pages 1, ISSN: 0005828759 *
ANNU. REV.MED., vol. 71, JPN6026012154, 2019, pages 47 - 58, ISSN: 0005828756 *
CANCER IMMUNOL RES., vol. 7, no. 11, JPN6026012156, 2019, pages 1864 - 1875, ISSN: 0005828758 *
CANCER RES., vol. Vol.80 (16_Supplement), JPN6026012155, 15 August 2020 (2020-08-15), pages 1 - 2, ISSN: 0005828757 *
MABS, vol. 9, no. 2, JPN6026012153, 2017, pages 182 - 212, ISSN: 0005828755 *

Also Published As

Publication number Publication date
IL302042A (en) 2023-06-01
AU2021359495A1 (en) 2023-04-13
EP4229096A1 (en) 2023-08-23
CN116390755A (zh) 2023-07-04
US20230220082A1 (en) 2023-07-13
CA3197463A1 (en) 2022-04-21
BR112023006989A2 (pt) 2024-01-02
MX2023004275A (es) 2023-05-02
EP4229096A4 (en) 2024-06-12
WO2022078357A1 (en) 2022-04-21
KR20230092932A (ko) 2023-06-26

Similar Documents

Publication Publication Date Title
US11566083B2 (en) Bispecific antibodies and uses thereof
JP7387743B2 (ja) 抗ｔｎｆｒｓｆ９抗体及びその使用
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
US20240002539A1 (en) Multispecific antibodies and uses thereof
KR102769109B1 (ko) 항―ｏｘ４０ 항체 및 그의 용도
US20230220082A1 (en) Anti-pd-1/cd40 bispecific antibodies and uses thereof
US20240109963A1 (en) Multispecific antibodies and uses thereof
WO2021098851A1 (en) Anti-ctla4/ox40 bispecific antibodies and uses thereof
KR102728939B1 (ko) 항-cd40 항체 및 그의 용도
US12463463B2 (en) Bispecific antibodies and uses thereof
WO2023143597A1 (en) Anti-ctla4/ox40 bispecific antibodies and uses thereof
JP2025503229A (ja) 抗ｈｅｒ２／ｔｒｏｐ２抗体及びその使用
WO2021041300A2 (en) Bispecific antibodies and uses thereof
JP2025523445A (ja) 抗ｓｉｇｌｅｃ１５抗体及びその使用
RU2859563C2 (ru) Биспецифические антитела к pd-1/cd40 и их применение
US20250270318A1 (en) Multispecific antibodies and uses thereof
HK40089128A (zh) 抗pd-1/cd40双特异性抗体及其用途
RU2783314C2 (ru) Антитела против ox40 и их применения
HK40064279A (en) Bispecific antibodies and uses thereof
HK40115176A (zh) 双特异性抗体及其用途
HK40064279B (zh) 双特异性抗体及其用途
HK40033364A (en) Bispecific antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331